680sir

680SIR is a fluorescent probe for near-IR live-cell super-resolution imaging.

Tozasertib (MK-0457) is a pan-Aurora kinase inhibitor (Kis: 0.6 18 4.6 nM for Aurora A Aurora B Aurora C). It shows selectivity against more than 190 different kinases.

NVP-QAV-680 is a potent and selective antagonist of CRTh2 receptor. NVP-QAV-680 has nM functional potency for inhibition of CRTh2 driven human eosinophil and Th2 lymphocyte activation in vitro.

Bavachin (Corylifolin) is a phytoestrogen that activates the estrogen receptors ERα and ERβ.

DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.

AB-680, a highly potent, reversible, and selective inhibitor of CD73 (an ectonucleotidase, Ki: 4.9 pM for hCD73) with anti-tumor activity, displays >10,000-fold selectivity over related ectonucleotidases CD39.

BAY-320 is a Bub1 inhibitor. With an IC50 of 680 nM for human Bub1 in the presence of 2 mM ATP.

Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation functio

SU1261, an IKK inhibitor, exhibits Ki values of 10 nM for IKKα and 680 nM for IKKβ. It effectively inhibits non-canonical NF-κB signaling in U2OS osteosarcoma cells.

TP-680 is a antagonist of cholecystokininA receptor.

CI 680 is a bio-active chemical.

T-808 is a tau tracer which may be used in radiographic labeling of Tau aggregates during Alzheimer's disease.

Tozasertib lactate is a potent and selective small-molecule inhibitor of the Aurora kinases which suppresses tumor growth by inducing apoptosis in tumor cells in which Aurora kinases are overexpressed.

NL-103 is a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. NL-103 comprises structural elements of Hh pathway inhibitor vismodegib, and histone deacetylase (HDAC) inhibitor vorinostat. NL-103 simultaneously and significantly inhibited both HDACs and Hh pathway. Importantly, NL-103 effectively overcame vismodegib resistance induced by Smoothened point mutations. Moreover, NL-103 significantly downregulated the expression of Gli2 which plays an important role in Hh pathway. NL-103 may be a promising compound for clinical development as a more effective Hh pathway inhibitor.

Leriglitazone (Hydroxypioglitazone) hydrochloride, a pioglitazone metabolite, acts as a PPARγ agonist, effectively stabilizing the PPARγ activation function-2 (AF-2) co-activator binding surface to enhance co-activator binding, which results in a modest improvement in transcriptional efficacy. It binds to the PPARγ C-terminal ligand-binding domain (LBD) with a dissociation constant (K i) of 1.2 μM and demonstrates transcriptional efficacy with an effective concentration (EC 50) of 680 nM [1].

AB-680 ammonium is a potent, reversible, and selective CD73 inhibitor (an ecto-nucleotidase), demonstrating a K i of 4.9 pM against hCD73 and exhibiting more than 10,000-fold selectivity over the related ecto-nucleotidase CD39, along with anti-tumor activity [1].

JMV6944 is a PXR agonist that competitively inhibits the binding of ligands to the ligand-binding domain (LBD) of human PXR, with an IC50 value of 680 nM. Additionally, JMV6944 induces the expression of CYP3A4 mRNA in cultures of freshly isolated primary human hepatocytes.

Anti-HER3 ERBB3 Antibody (4V862) is a Rabbit IgG monoclonal antibody targeting Human HER3 ERBB3.